Pancreatic cancer (PC) is a highly malignant tumor that is resistant to chemotherapy, radiotherapy and immunotherapy.
Combination chemotherapy regimens are the standard first-line regimens for metastatic disease, with a median survival < 12 months.
Although recurrent genomic alterations such as the
